Novartis AG

NOVN

CH0012005267

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 16:30:12 24/05/2024 BST			5-day change	1st Jan Change
91.74 ^CHF	-1.11%		-1.75%	+8.09%

05-24	NOVARTIS AG : Deutsche Bank remains its Buy rating	ZD
05-23	Berenberg Raises Price Target on Novartis to CHF77 From CHF74, Maintains Hold Rating	MT

Novartis AG acquired SanReno Therapeutics from Pivotal bioVenture Partners China, Versant Venture Management, LLC, Samsara BioCapital LLC, Frazier Healthcare Partners managed by Frazier Management, L.L.C. and Frazier Life Sciences Management, LP.

January 04, 2024

Novartis AG (SWX:NOVN) acquired SanReno Therapeutics from Pivotal bioVenture Partners China, Versant Venture Management, LLC, Samsara BioCapital LLC, Frazier Healthcare Partners managed by Frazier Management, L.L.C. and Frazier Life Sciences Management, LP on January 5, 2024. Morgan Stanley is acting as financial advisor to SanReno Therapeutics.

Novartis AG (SWX:NOVN) completed the acquisition of SanReno Therapeutics from Pivotal bioVenture Partners China, Versant Venture Management, LLC, Samsara BioCapital LLC, Frazier Healthcare Partners managed by Frazier Management, L.L.C. and Frazier Life Sciences Management, LP on January 5, 2024.

Latest news about Novartis AG

NOVARTIS AG : Deutsche Bank remains its Buy rating	05-24	ZD
Berenberg Raises Price Target on Novartis to CHF77 From CHF74, Maintains Hold Rating	05-23	MT
NOVARTIS AG : Berenberg remains Neutral	05-23	ZD
Novartis' Cosentyx Receives Canadian Approval for Hidradenitis Suppurativa Treatment	05-23	MT
Sandoz: Marketing authorization for Wyost and Jubbonti in the EU	05-22	CF
Dpa-AFX Overview: COMPANIES from 16.05.2024 - 15:15	05-16	DP
Novartis: presents results of tender offer for MorphoSysy	05-16	CF
Novartis Takeover Bid for MorphoSys Tops Minimum Acceptance Threshold	05-16	MT
Novartis to present results at ASCO and EHA	05-15	CF
Novartis highlights pioneering innovation in CML with data from Scemblix(R) Phase III ASC4FIRST study in newly diagnosed patients at ASCO and EHA	05-15	DJ
Legend Biotech 1Q Loss Narrows with Higher Carvykti Sales	05-13	DJ
Novartis’ Scemblix Gets Third US FDA Breakthrough Therapy Designation	05-10	MT
Novartis Gets FDA Breakthrough Therapy Designation for Scemblix	05-10	DJ
NOVARTIS AG : UBS maintains a Buy rating	05-06	ZD
Health Care Flat Amid Mixed Earnings -- Health Care Roundup	05-02	DJ
Sector Update: Health Care Stocks Softer Late Afternoon	05-02	MT
Sector Update: Health Care Stocks Retreat Thursday Afternoon	05-02	MT
Top Midday Stories: Novo Nordisk, Linde Shares Fall Post-Earnings; Peloton Shares Plummet After Announcing Job Cuts, CEO Change; Exxon-Pioneer Deal Gets FTC Approval With One Caveat	05-02	MT
News Highlights : Top Company News of the Day - Thursday at 11 AM ET	05-02	DJ
Novartis AG to Acquire Mariana Oncology in Deal Valued Up to $1.75 Billion.	05-02	MT
News Highlights : Top Company News of the Day - Thursday at 9 AM ET	05-02	DJ
Novartis: acquisition of US-based Mariana Oncology	05-02	CF
Switzerland's Novartis to Buy US-based Mariana Oncology for $1 Billion Upfront	05-02	MT
Novartis to Buy Mariana Oncology, Pay $1 Billion Upfront	05-02	MT
Novartis AG to Acquire Mariana Oncology	05-02	MT

Chart Novartis AG

Duration

Period

More charts

Company Profile

Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows: - oncology (29.9%); - immunology (17.2%); - cardiovascular, renal and metabolic diseases (14.1%); - neuroscience (8.9%). The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products. At the end of 2023, Novartis AG had 33 production sites worldwide. Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).

Sector

Pharmaceuticals

Calendar

01/06/2024 - American Society of Clinical Oncology Annual Meeting

Related indices

SMI , STOXX EUROPE 600 (EUR)

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

NOVARTIS : 2024 has started on a strong note; guidance upgraded

April 23, 2024 at 06:24 pm

Vas Narasimhan, CEO of Novartis: 40% margin by 2027

April 23, 2024 at 12:18 pm

Novartis AG : Sandoz takes its first steps on the stock exchange

October 04, 2023 at 03:32 pm

More Strategies

Ratings for Novartis AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

100.4 USD

Average target price

108 USD

Spread / Average Target

+7.64%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
NOVARTIS AG	+8.09%	205B
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B
SANOFI	-0.27%	121B

Other Pharmaceuticals

Novartis AG

Equities

NOVN

CH0012005267

Pharmaceuticals

Novartis AG acquired SanReno Therapeutics from Pivotal bioVenture Partners China, Versant Venture Management, LLC, Samsara BioCapital LLC, Frazier Healthcare Partners managed by Frazier Management, L.L.C. and Frazier Life Sciences Management, LP.

EPS Revisions